Multilevel generalised linear model of total annual healthcare costs after SVR in postintervention years 1–4
Total costs | Children (0–18 years, n=325) | Adults (>18 years, n=13 944) | ||||
Parameter | β | 95% CI | P value | β | 95% CI | P value |
Intercept | 16 931 | −36 190 to 70 051 | 0.533 | 11 338 | 9906 to 12 770 | <0.0001 |
Time (compared with year 1 excluding intervention costs) | ||||||
Intervention period* | 21 841 | 20 857 to 22 825 | <0.0001 | 25 492 | 25 248 to 25 736 | <0.0001 |
Year 2 | −11 519 | −67 302 to 44 264 | 0.686 | −2904 | −3779 to −2030 | <0.0001 |
Year 3 | −14 952 | −67 272 to 37 368 | 0.576 | −1862 | −3421 to −302 | 0.019 |
Year 4 | −6170 | −64 405 to 52 065 | 0.836 | 396 | −1627 to 2420 | 0.701 |
Death | 6106 | 4784 to 7428 | <0.0001 | |||
Age (compared with elderly) | ||||||
Children (0–18 years) | ||||||
Young adults (19–60 years) | −1179 | −2290 to −68 | 0.038 | |||
Middle aged (61–70 years) | −2441 | −3359 to −1524 | <0.0001 | |||
Male | 1133 | −30 369 to 32 635 | 0.944 | −1110 | −1911 to −310 | 0.007 |
Comorbidity (compared with no comorbidity) | ||||||
COPD, DM, kidney disease and/or HF | 6543 | 5328 to 7757 | <0.0001 | |||
Hypertension | 1309 | 67 to 2550 | 0.039 | |||
Other comorbidities | 1990 | 218 to 3761 | 0.028 | |||
SES†(compared with highest SES: 71–100) | ||||||
SES 0–20 | 8553 | −36 202 to 53 308 | 0.708 | 1160 | 34 to 2285 | 0.044 |
SES 21–40 | 2878 | −41 065 to 46 821 | 0.898 | 301 | −823 to 1426 | 0.599 |
SES 41–70 | 2505 | −37 038 to 42 048 | 0.901 | 887 | −128 to 1901 | 0.087 |
Complications | ||||||
Atrial fibrillation | 2985 | 1673 to 4296 | <0.0001 | |||
Acute kidney inury | 19 639 | 16 611 to 22 667 | <0.0001 | |||
Stroke | 7755 | 6181 to 9329 | <0.0001 | |||
TIA | 623 | −2157 to 3403 | 0.661 | |||
Endocarditis | 21 572 | 18 999 to 24 144 | <0.0001 | |||
Myocardial infarction | 13 192 | 9291 to 17 092 | <0.0001 | |||
Pacemaker implantation | 15 947 | 13 816 to 18 079 | <0.0001 | |||
Reintervention | 30 094 | 25 455 to 34 733 | <0.0001 |
NB: 3622 SVR and all TVI patients were excluded because follow-up <1 year.
*Includes costs of heart valve implantation and ICU stay but no other costs of the first postintervention year (these are included in the reference group of this variable).
†Higher percentiles represent higher SES.
COPD, chronic Obstructive Pulmonary Disease; DM, diabetes mellitus; HF, heart failure; ICU, intensive care unit; SES, socioeconomic status; SVR, surgical heart valve replacement; TIA, transient ischaemic attack.